4//SEC Filing
Georgantas Robert William III 4
Accession 0001140361-22-018734
CIK 0001439725other
Filed
May 10, 8:00 PM ET
Accepted
May 11, 9:42 PM ET
Size
12.0 KB
Accession
0001140361-22-018734
Insider Transaction Report
Form 4
BIODESIX INCBDSX
Georgantas Robert William III
DirectorSVP, Rsrch & Trans'l Science
Transactions
- Exercise/Conversion
Common Stock
2022-05-09+5,647→ 20,287 total - Exercise/Conversion
Restricted Stock Units
2022-05-09−1,971→ 29,566 total→ Common Stock (1,971 underlying) - Sale
Common Stock
2022-05-10$1.83/sh−2,004$3,667→ 18,283 total - Exercise/Conversion
Restricted Stock Units
2022-05-09−3,676→ 18,377 total→ Common Stock (3,676 underlying)
Holdings
- 100(indirect: By UGMA Account)
Common Stock
Footnotes (6)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").
- [F2]These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.
- [F3]These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.
- [F4]These Shares were sold automatically to cover taxes upon the vesting of RSUs.
- [F5]The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.945, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]Includes 1,262 and 2,604 Shares acquired under the BDSX stock purchase plan on August 31, 2021 and February 28, 2022, respectively.
Documents
Issuer
BIODESIX INC
CIK 0001439725
Entity typeother
Related Parties
1- filerCIK 0001827728
Filing Metadata
- Form type
- 4
- Filed
- May 10, 8:00 PM ET
- Accepted
- May 11, 9:42 PM ET
- Size
- 12.0 KB